This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CIDEA / Lipid transferase CIDEA · Western blot design guide
Design a Western Blot for CIDEA
Real validated CIDEA Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-CIDEA WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
CIDEA Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~24.7 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | — | |
| Caveat | Peptide competition control | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated CIDEA Western Blot Protocols
The A02671 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human brain tissue lysate in the absence (A) or presence (B) of peptide (A02671P) (catalog A02671) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A02671 · 1:2000 (catalog A02671) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected CIDEA Western Blot Band Size?
CIDEA is predicted at 24.7 kDa; homodimer formation could affect migration, but no empirical band size or visible dimer band is established.
| Band near 24.7 kDa | Consistent with the predicted CIDEA monomer; confirm identity with peptide competition. |
| Band near 49 kDa | Could reflect a retained homodimer; its migration is unverified. |
| Stronger band in a lipid droplet fraction | Consistent with CIDEA enrichment at lipid droplet contact sites. |
| Band in a nuclear fraction | Consistent with the annotated nuclear location; confirm its identity. |
💡Expected CIDEA appearanceThe predicted CIDEA monomer is 24.7 kDa; no empirical band size is supplied, so confirm a band near that size with peptide competition and appropriate fraction controls.
| Predicted monomer mass | Places the full-length CIDEA polypeptide near 24.7 kDa. |
| 219-residue sequence | Underlies the predicted 24.7 kDa full-length mass. |
| Homodimer formation | Could produce a band near twice the monomer size if the dimer survives sample preparation. |
| Dissociation of the homodimer | Would favor migration at the predicted monomer size. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | CIDEA is enriched at lipid droplet contact sites and may be poorly represented in the sampled lysate. | Check a lipid droplet-enriched fraction and verify extraction and loading. |
| Band higher than expected | A CIDEA homodimer may have survived sample preparation. | Compare denatured and untreated samples, and confirm identity by peptide competition. |
| Band lower than expected | The supplied features do not establish a smaller CIDEA product. | Check sample integrity and test band identity with peptide competition. |
| Multiple bands | Monomer and retained homodimer are possible, but other bands remain unidentified. | Compare sample preparation conditions and assess each band by peptide competition. |
| Weak or no signal | Lipid droplet enrichment may limit CIDEA abundance in the tested fraction. | Check a lipid droplet-enriched fraction and verify loading. |
Experiment evidence
Western blot images showing CIDEA band
A02671 · CIDEA
A02671-1 · CIDEA
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for CIDEA Western blot
🧪For positive controls for CIDEA in Western blot, you can use no HPA-supported sample from the supplied evidence; a positive sample must be established experimentally.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: CIDEA is enriched at lipid droplet contact sites, but the supplied HPA data provide no tissue controls.
HPA tissue expression evidence for CIDEA
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced CIDEA Western Blot Tips
Deeper troubleshooting and optimisation questions for CIDEA, answered from its protein features.
Where should the CIDEA band appear?
Band shift · CIDEA has a predicted mass of 24.7 kDa. No observed Western-blot band position was supplied, so use 24.7 kDa as a reference, not a confirmed apparent mass.
Could CIDEA isoforms explain multiple bands?
Isoforms · The supplied UniProt record lists one isoform and no alternative sequence. It therefore provides no isoform-based explanation for multiple bands.
Do annotated modifications predict a CIDEA band shift?
PTM · The supplied record lists no modified residues or glycosylation sites. It provides no annotated modification that predicts a shift; it also does not establish why an observed band might differ from 24.7 kDa.
Does this guide establish induction of CIDEA?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for CIDEA?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A02671 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should CIDEA bands be compared quantitatively?
Quantitation · Because CIDEA is associated with lipid droplets and the nucleus, compare samples prepared from the same fraction and use a suitable loading normalization for that fraction. State whether the measurement represents total lysate or an enriched fraction.
Could a higher band be a CIDEA dimer?
Interpretation · CIDEA is annotated as a homodimer and interacts with CIDEC. A higher band could prompt investigation of complex formation, but these interactions alone do not establish that a dimer or complex survives Western-blot preparation or explains the band.
CIDEA is annotated at lipid droplets, with enrichment at lipid-droplet contact sites, and also in the nucleus. Choose and report the fraction being measured; results from different fractions may reflect different CIDEA pools.
CIDEA is annotated at lipid droplets, with enrichment at lipid-droplet contact sites, and also in the nucleus. Choose and report the fraction being measured; results from different fractions may reflect different CIDEA pools.
Boster reagents
CIDEA Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-CIDE-A Antibody
Cat # A02671
Real WB data
Anti-CIDE-A Antibody
Cat # A02671-1
Two anti-CIDEA antibodies have Western blot images: A02671 in human brain lysate at 1:2000, with and without peptide, and A02671-1 in mouse heart lysate at 1:500. These images document the stated sample conditions only.
Which to pick: For human samples, consider A02671, which lists human reactivity and shows a human brain blot. For mouse samples, A02671-1 lists mouse reactivity and shows a mouse heart blot; it also lists human reactivity, but its supplied image uses mouse tissue.
Source: BosterBio CIDEA gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry O60543.
- Human Protein Atlas. CIDEA tissue expression.
- PMC13063659 — target-verified WB comparison
- PMC12384258 — target-verified WB comparison
- PMC4979534 — target-verified WB comparison